| Literature DB >> 33974730 |
Yu-Shien Sung1, Wangbin Wu1, Megan A Ewbank1, Rachel D Utterback1, Michael T Marty1, Elisa Tomat1.
Abstract
The central role of iron in tumor progression and metastasis motivates the development of iron-binding approaches in cancer chemotherapy. Disulfide-based prochelators are reductively activated upon cellular uptake to liberate thiol chelators responsible for iron sequestration. Herein, a trimethyl thiosemicarbazone moiety and the imidazole-2-thione heterocycle are incorporated in this prochelator design. Iron binding of the corresponding tridentate chelators leads to the stabilization of a low-spin ferric center in 2 : 1 ligand-to-metal complexes. Native mass spectrometry experiments show that the prochelators form stable disulfide conjugates with bovine serum albumin, thus affording novel bioconjugate prochelator systems. Antiproliferative activities at sub-micromolar levels are recorded in a panel of breast, ovarian and colorectal cancer cells, along with significantly lower activity in normal fibroblasts.Entities:
Keywords: albumin; cancer; imidazole-2-thione; iron chelation; thiosemicarbazone
Mesh:
Substances:
Year: 2021 PMID: 33974730 PMCID: PMC8448912 DOI: 10.1002/cmdc.202100278
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.540